Therapeutic doses of hydroxyurea cause telomere dysfunction and reduce TRF2 binding to telomeres

Cancer Biology and Therapy

Volumn 8, Issue 12, 2009, Pages 1136-1145

  Snyder, Andrew R ^a   Zhou, Jing ^a   Deng, Zhong ^a   Lieberman, Paul M ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Hydroxyurea; Replication; Telomere; TERRA; TRF2

Indexed keywords

HYDROXYUREA; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 2;

ARTICLE; CELL CYCLE S PHASE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME REPLICATION; CONTROLLED STUDY; DNA BINDING; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TELOMERE;

EID: 68049139532     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.12.8446     Document Type: Article

References (36)

1. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res 2008; 68:3551-7.
2. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
3. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.
4. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006; 12:1133-8.
5. Cech TR. Beginning to understand the end of the chromosome. Cell 2004; 116:273-9.
6. Riethman H. Human telomere structure and biology. Annu Rev Genomics Hum Genet 2008; 9:1-19.
7. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005; 19:2100-10.
8. Karlseder J, Hoke K, Mirzoeva OK, Bakkenist C, Kastan MB, Petrini JH, et al. The telomeric protein TRF2 binds the ATM kinase and can inhibit the ATM-dependent DNA damage response. PLoS biology 2004; 2:240.
9. Zhu X-D, Kuster B, Mann M, Petrini JHJ, de Lange T. Cell cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat Genet 2000; 25:347-52.
10. Celli GB, de Lange T. DNA processing is not required for ATM-mediated telomere damage response after TRF2 deletion. Nat Cell Biol 2005; 7:712-8.
11. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92:401-13.
12. Wang RC, Smogorzewska A, de Lange T. Homologous recombination generates T-loop-sized deletions at human telomeres. Cell 2004; 119:355-68.
13. Atanasiu C, Deng Z, Wiedmer A, Norseen J, Lieberman PM. ORC binding to TRF2 stimulates OriP replication. EMBO Rep 2006; 7:716-21.
14. Deng Z, Dheekollu J, Broccoli D, Dutta A, Lieberman PM. The origin recognition complex localizes to telomere repeats and prevents telomere-circle formation. Curr Biol 2007; 17:1989-95.
15. Bell SP. The origin recognition complex: from simple origins to complex functions. Genes Dev 2002; 16:659-72.
16. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 2007; 448:1068-71.
17. Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P, Ambros PF. Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. Gen Chrom Cancer 2007; 46:130-42.
18. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19:1-10.
19. Shechter D, Costanzo V, Gautier J. ATR and ATM regulate the timing of DNA replication origin firing. Nat Cell Biol 2004; 6:648-55.
20. Deng Z, Lezina L, Chen CJ, Shtivelband S, So W, Lieberman PM. Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. Mol Cell 2002; 9:493-503.
21. Zhou J, Snyder A, Lieberman PM. Epstein-barr virus episome stability is coupled to a delay in replication timing. J Virol 2008; 83:2154-62.
22. Chodosh J, Holder VP, Gan YJ, Belgaumi A, Sample J, Sixbey JW. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 1998; 177:1194-201.
23. Srinivas SK, Sample JT, Sixbey JW. Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt's lymphoma cell line. J Infect Dis 1998; 177:1705-9.
24. Azzalin CM, Reichenback P, Khoriauli L, Giulotto E, Lingner J. Telomeric Repeat Containing RNA and RNA surveillance factors at mammalian chromosome ends. Science 2007; 318:798-801.
25. Schoeftner S, Blasco MA. Developmentally regulated transcription of mammalian telomeres by DNA-dependent RNA polymerase II. Nat Cell Biol 2008; 10:228-36.
26. Tanaka H, Mendonca MS, Bradshaw PS, Hoelz DJ, Malkas LH, Meyn MS, et al. DNA damage-induced phosphorylation of the human telomere-associated protein TRF2. Proc Natl Acad Sci USA 2005; 102:15539-44.
27. Fruchtman SM. Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 2004; 41:18-22.
28. Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br J Hematol 2003; 120:177-86.
29. Vassallo C, Passamonti F, Merante S, Ardigo M, Nolli G, Mangiacavalli S, et al. Mucocutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001; 26:141-8.
30. De Benedittis M, Petruzzi M, Giardina C, Lo Muzio L, Favia G, Serpico R. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin Exp Dermatol 2004; 29:605-7.
31. Dantzer F, Giraud-Panis MJ, Jaco I, Ame JC, Schultz I, Blasco M, et al. Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2. Mol Cell Biol 2004; 24:1595-607.
32. Wu Y, Mitchell TR, Zhu XD. Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms. Mech Ageing Dev 2008; 129:602-10.
33. Verdun RE, Karlseder J. The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres. Cell 2006; 127:709-20.
34. 2 of the cell cycle. Mol Cell 2005; 20:551-61.
35. Tatsumi Y, Ezura K, Yoshida K, Yugawa T, Narisawa-Saito M, Kiyono T, et al. Involvement of human ORC and TRF2 in pre-replication complex assembly at telomeres. Genes Cells 2008; 13:1045-59.
36. Gottifredi V, Shieh S, Taya Y, Prives C. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proc Natl Acad Sci USA 2001; 98:1036-41.